@article {Anderson2021.04.16.21255130, author = {Mark Anderson and Vera Holzmayer and Ana Vallari and Russell Taylor and James Moy and Gavin Cloherty}, title = {Expanding access to SARS-CoV-2 IgG and IgM serologic testing using fingerstick whole blood, plasma, and rapid lateral flow assays}, elocation-id = {2021.04.16.21255130}, year = {2021}, doi = {10.1101/2021.04.16.21255130}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Serologic testing for SARS-CoV-2 antibodies can be used to confirm diagnosis, estimate seroprevalence, screen convalescent plasma donors, and assess vaccine efficacy. Several logistical and infrastructure challenges limit access to SARS-CoV-2 serologic testing. Dried blood spot (DBS) samples have been used for serology testing of various diseases in resource-limited settings. We examined the use of DBS samples and capillary blood (fingerstick) plasma collected in Microtainer tubes for SARS-CoV-2 testing with the automated Abbott ARCHITECT{\texttrademark} SARS-CoV-2 IgG (List 6R86) and IgM assays and use of venous whole blood with a prototype PANBIO{\texttrademark} rapid point-of-care lateral flow SARS-CoV-2 IgG assay. The ARCHITECT{\texttrademark} SARS-CoV-2 IgG assay was initially optimized for use with DBS, venous and capillary plasma, and venous whole blood collected from patients with symptoms and PCR-confirmed COVID-19 and negative asymptomatic controls. Assay linearity and reproducibility was confirmed with 3 contrived DBS samples, with sample stability and signal recovery after 14 days at room temperature. ARCHITECT{\texttrademark} SARS-CoV-2 IgG and IgM assay results showed high concordance between fingerstick DBS and venous DBS samples, and between fingerstick DBS and venous whole blood samples (n=61). Discordant results were seen in 3 participants (2 IgG, 1 IgM) who were in the process of seroreversion at the time of sample collection and had results near the assay cutoff. Use of fingerstick plasma collected in Microtainer tubes (n=109) showed 100\% concordant results (R2=0.997) with matched patient venous plasma on the ARCHITECT{\texttrademark} SARS-CoV-2 IgG assay. High concordance of assay results (92.9\% positive, 100\% negative) was also observed for the PANBIO{\texttrademark} SARS-CoV-2 IgG assay compared to the ARCHITECT{\texttrademark} SARS-CoV-2 IgG assay run with matched venous plasma (n=61). Fingerstick DBS and plasma samples are easy and inexpensive to collect and, along with the use of rapid point-of-care testing platforms, will expand access to SARS-CoV-2 serology testing, particularly in resource-limited areas.Competing Interest StatementMA, VH, AV, RT, and GC are employees and shareholders of Abbott Laboratories. JM has no conflicts to disclose.Funding StatementFunding for this work was supported by Abbott Laboratories.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was approved by the Institutional Review Board at Rush University Medical Center (IRB$\#$ 20041610-IRB01).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe Data that supports the findings of this study are available from Abbott Laboratories but restrictions apply to the availability of these data. Data are available from the authors upon reasonable request and with the permission of Abbott Laboratories.}, URL = {https://www.medrxiv.org/content/early/2021/04/18/2021.04.16.21255130}, eprint = {https://www.medrxiv.org/content/early/2021/04/18/2021.04.16.21255130.full.pdf}, journal = {medRxiv} }